Curocell Inc. (KOSDAQ:372320)
South Korea
· Delayed Price · Currency is KRW
44,900
+1,700 (3.94%)
At close: Dec 5, 2025
Curocell Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Cost of Revenue | 16.33 | 10.49 | 14.19 |
| Gross Profit | -16.33 | -10.49 | -14.19 |
| Selling, General & Admin | 4,628 | 4,632 | 3,821 |
| Research & Development | 32,736 | 31,864 | 27,191 |
| Amortization of Goodwill & Intangibles | 54.88 | 3.87 | 1.5 |
| Other Operating Expenses | 88.43 | 14.51 | 11.22 |
| Operating Expenses | 37,610 | 36,614 | 31,116 |
| Operating Income | -37,627 | -36,624 | -31,130 |
| Interest Expense | -3,687 | -2,603 | -2,431 |
| Interest & Investment Income | 453.91 | 938.26 | 617.54 |
| Currency Exchange Gain (Loss) | -15.25 | -24.34 | -14.64 |
| Other Non Operating Income (Expenses) | 1,617 | 83.35 | 3,305 |
| EBT Excluding Unusual Items | -39,258 | -38,230 | -29,652 |
| Gain (Loss) on Sale of Assets | 1.24 | -8.18 | -11.24 |
| Pretax Income | -39,257 | -38,238 | -29,664 |
| Income Tax Expense | 1.1 | 1.1 | -88.73 |
| Net Income | -39,258 | -38,239 | -29,575 |
| Net Income to Common | -39,258 | -38,239 | -29,575 |
| Shares Outstanding (Basic) | 14 | 14 | 12 |
| Shares Outstanding (Diluted) | 14 | 14 | 12 |
| Shares Change (YoY) | 3.99% | 18.10% | - |
| EPS (Basic) | -2754.74 | -2736.20 | -2499.18 |
| EPS (Diluted) | -2754.74 | -2736.20 | -2499.18 |
| Free Cash Flow | -30,968 | -28,863 | -46,428 |
| Free Cash Flow Per Share | -2173.07 | -2065.28 | -3923.32 |
| EBITDA | -31,480 | -30,289 | -26,424 |
| D&A For EBITDA | 6,146 | 6,335 | 4,706 |
| EBIT | -37,627 | -36,624 | -31,130 |
| Advertising Expenses | - | 43.48 | 45.38 |
Source: S&P Capital IQ. Standard template.
Financial Sources.